...Susanne Herbst; Patrick A. Lewis; Huw R. Morris Parkinson’s disease (PD) is conventionally described as an α-synuclein aggregation disorder, defined by Lewy bodies and neurites, and mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common autosomal dominant cause of PD. However, LRRK2...

...Yu Tian; Yuwen Cao; Rong Chen; Yufeng Jing; Lin Xia; Shiqing Zhang; Huaxi Xu; Zhaoliang Su In the subacute Parkinson’s disease (PD) mice model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), injection of HMGB1 competitive inhibitor protein HMGB1 A box and the ethyl pyruvate (EP...

... degeneration include Menkes disease and Wilson's disease but a large body of evidence also implicates disrupted copper pathways in other neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Huntington's disease and prion diseases. In this short review...

... mice. SP failed to interfere with microglial proliferation but induced migration through a NK1R /protein kinase Cδ (PKCδ)/NADPH oxidase (NOX2) pathway-dependent manner. chemotaxis microglia distribution Parkinson's disease • We have reported that SP potentiates microglial activation...

... permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited. aging Alzheimer's disease atherosclerosis heart failure longevity Parkinson's disease telomerase telomere The 2009 Nobel Prize in Physiology or Medicine...

... patients with Parkinson's disease (PD) with Hoehn and Yahr stages 1–4. Patients were investigated once with their regular treatment and once after 12 h of interruption of L -dopa treatment. L -Dopa intake significantly reduced systolic and diastolic blood pressure, heart rate and plasma noradrenaline...

.... Autonomic dysfunction OH, impotence, urinary incontinence and constipation. dementia with Lewy bodies (DLB) genetic basis Lewy body disease Parkinson's disease Friederich Lewy in the early 1900s first identified the intraneuronal inclusions in the substantia nigra of patients with PD...

...Shushant Jain; Nicholas W. Wood; Daniel G. Healy Major progress has been made in the last decade in understanding the genetic basis of PD (Parkinson's disease) with five genes unequivocally associated with disease. As a result, multiple pathways have been implicated in the pathogenesis of PD...

... linked either pharmacologically or biochemically to central noradrenergic neuronal activity. 4. Cerebrospinal fluid dopamine β-hydroxylase was not changed in essential hypertension. In Parkinson's disease, cerebrospinal fluid dopamine β-hydroxylase was markedly diminished (16.3 ± 2.9 versus 31.3 ± 1.4 ng...

...H. S. Markus; M. Cox; A. M. Tomkins 1. Resting energy expenditure was measured, by indirect calorimetry, in 12 patients with Parkinson's disease and in eight healthy age-matched control subjects. In the patients with Parkinson's disease measurements were made in both the untreated state and after...

...D. A. Bender; C. J. Earl; A. J. Lees 1. Benserazide and carbidopa, decarboxylase inhibitors used in the treatment of Parkinson's disease, have been shown to inhibit the enzyme kynurenine hydrolase in rat and mouse liver. This results in reduced synthesis of nicotinamide coenzymes from tryptophan...

...C. S. Wilcox; M. J. Aminoff; J. D. H. Slater 1. The renal excretion of sodium by five patients with autonomic failure (Shy—Drager syndrome) was compared with a matched control group who had normal autonomic reflexes (Parkinson's disease). For 8 or 9 days the daily sodium intake was reduced to 17...

...C. S. Wilcox; M. J. Aminoff; A. B. Kurtz; J. D. H. Slater 1. The effect on plasma renin activity (PRA) of dopamine and noradrenaline infusions was studied in three patients with Shy—Drager syndrome, three patients with Parkinson's disease and normal autonomic reflexes, and three healthy volunteers...